[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337057-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-337057-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","single-center-evaluation-of-sensitivity-and-specificity-of-celldetect-assay-in-early-bladder-cancer-patients","Single center evaluation of sensitivity and specificity of CellDetect assay in early bladder cancer patients","","Single-center retrospective evaluation assesses the diagnostic performance of the CellDetect assay for early bladder cancer by comparing it with standard clinical diagnostic approaches. Between August 2020 and July 2022, 148 patients with bladder masses were enrolled after imaging excluded cases without detectable lesions. Urine samples were tested with CellDetect, followed by cystoscopy or diagnostic transurethral resection. Results across all patients show sensitivity of 82.1% and specificity of 64.2%, with subgroup differences by prior bladder cancer history.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/single-center-evaluation-of-sensitivity-and-specificity-of-celldetect-assay-in-early-bladder-cancer-patients/337057/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/single-center-evaluation-of-sensitivity-and-specificity-of-celldetect-assay-in-early-bladder-cancer-patients/337057.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What diagnostic method was evaluated in the study?","Question",{"text":63,"@type":64},"The study evaluated the CellDetect urine assay, focusing on its sensitivity and specificity for early bladder cancer detection.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were patients selected for inclusion?",{"text":68,"@type":64},"Patients were enrolled from August 2020 to July 2022 for suspected bladder cancer based on hematuria or irritative voiding symptoms or imaging showing a bladder mass, and they were required to be at least 18 years old.",{"name":70,"@type":61,"acceptedAnswer":71},"What were the overall sensitivity and specificity results?",{"text":72,"@type":64},"For all patients, the overall sensitivity was 82.1% and the overall specificity was 64.2%.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},337057,1790211974,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSingle center evaluation of sensitivity and specificity of CellDetect assay in early bladder cancer patients  \nWenbo Gao􀀍 & Zhiling Lou  \nUntil recently, the main diagnostic methods for bladder cancer (BC) are still voided urine cytology and cystoscopy, and many drawbacks persist. In this retrospective study, we evaluated the sensitivity and specificity of the CellDetect assay in the detection of BC with comparison to standard diagnostic methods. Between August 2020 and July 2022, B-ultrasonography or computed tomography (CT) scan was performed for patients with hematuria or irritative voiding symptoms. If no bladder mass was detected, the patient was excluded. A total of 148 patients with bladder mass formed the final study cohort. The patients’ urine samples were measured with CellDetect assay, followed by cystoscopy or diagnostic transurethral resection of bladder tumor. The patients were divided into two groups based on previous history of BC: group P and group R. The analysis included descriptive statistics and percentages. Finally, 115 cases had a positive CellDetect result, with 68 cases in group P and 47 in group R, respectively. And 134 cases revealed malignant tumor pathologically. The overall sensitivity and specificity for all patients were 82.1% and 64.2%, respectively. Concerning the subgroups, the respective sensitivity and specificity were: in group P-81.0% and 50.0%; and in group R-85.2% and 83.3%, respectively. In conclusion, CellDetect assay demonstrated significant performance for diagnosis of BC: it can identify BC patients at early stage with significant diagnostic performance and good reliability. This assay might develop novel methods and ideas for future clinical practice.  \nOver the past decades, the management of BC has witnessed several advancements, such as immune checkpoint inhibitor (ICI) therapy, antibody-drug conjugates (ADCs), trimodality bladder-sparing therapy, gene therapy; and better outcomes have been obtained1. However, breakthrough progression has not been made in the diagnostic methods of BC, except some modifications based on urine cytology and cystoscopy. Therefore, early diagnosis of BC, which is of clinical importance for treatment decisions, remains a rather great challenge.  \nWe are all aware that if BC patients are detected as early as being confined to the mucosa or lamina propria, they can receive appropriately treatment, resulting in better outcomes and quality of life (QOL)2. But if the diagnosis is delayed, patients would harbor higher stage and grade cancers. Currently, among patients who receive an initial diagnosis of BC, about 25% have muscle-invasive BC (MIBC) or metastatic disease, leading to worse prognosis3. Thus, BC should be detected at its earliest and most localized stage.  \nFor nearly halfa century, voided urine cytology has been the main clinical method for detecting BC. But studies have shown that its sensitivity is not very satisfactory4, thus it is usually seen as a basic and crude examination. Meanwhile, although cystoscopy is considered the gold standard of diagnosis for BC, the procedure has innate adverse outcomes, for example, inadvertent damage of urethra or bladder, infection, as well as uncomfortable feelings for patients.  \nClinically, improvement in the accuracy of early diagnosis for BC is strongly required. More sensitive, noninvasive, and cost-effective examination method is an ongoing pursuit for urologists. Recently, some novel methods of urine-based cancer detection have been proposed, such as bladder tumor antigen, Xpert Bladder Cancer Detection, UroVysion, Oncuria5, nuclear matrix protein-22. But for many reasons, such as increased cost, needing for trained personnel or expensive equipment, or not a point-of-care assay, the clinical applications were not quite satisfactory, and they could not replace cystoscopy completely.  \nA recently developed urine test tech","cbCaifUFZTWChdbn","https://ap.wps.com/l/cbCaifUFZTWChdbn","pdf",1443072,"English","# Materials and methods\n## Patients\n## Assay procedure and follow-up diagnostics","[{\"question\":\"What diagnostic method was evaluated in the study?\",\"answer\":\"The study evaluated the CellDetect urine assay, focusing on its sensitivity and specificity for early bladder cancer detection.\"},{\"question\":\"How were patients selected for inclusion?\",\"answer\":\"Patients were enrolled from August 2020 to July 2022 for suspected bladder cancer based on hematuria or irritative voiding symptoms or imaging showing a bladder mass, and they were required to be at least 18 years old.\"},{\"question\":\"What were the overall sensitivity and specificity results?\",\"answer\":\"For all patients, the overall sensitivity was 82.1% and the overall specificity was 64.2%.\"}]","Single center evaluation of sensitivity and specificity of CellDetect assay in early bladder cancer patients | PDF",1790017571,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/239713b616a6a84b0beab575cc76fd91.webp",983,1291,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c926db833eafd21e6601e400fe5e66c6.webp",982,1290,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd0e8e938574a5118d62c9df7d70d7c0.webp",981,1289,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c45bf00db302adec2f492cc1f302b883.webp",980,1287]